Efficacy and Safety of PRM-151 in Myelofibrosis


Efficacy and Safety of PRM-151 in Myelofibrosis
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/18/16)

Verstovsek S et al. PRM-151 in myelofibrosis: Durable efficacy and safety at 72 weeks. Proc ASH 2015;Abstract 56.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.